- Dermira (NASDAQ:DERM) is up 5.5%, with Evercore seeing solid market opportunity after the company's prescription wipe for excessive underarm sweat won FDA approval.
- Some 800,000 people are treated for primary axillary hyperhidrosis, analyst Umer Raffat notes, and peak risk-adjusted sales are modeled at $200M. Investors now will look toward phase 2B data for lebrikizumab in atopic dermatitis due early next year. (h/t Bloomberg)
- Raffat has a price target of $16, implying 73% further upside from here.